CADL Candel Therapeutics, Inc.
Nasdaq · SEC CIK 1841387 · EDGAR
- Bought, last 12 months
- $3.00M 1 purchases by 1 insiders
- Sold, last 12 months
- $3.55M 4 sales by 3 insiders
- Filings on record
- 169 since 2021-07-29, latest 2026-09-11 18:12
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Tak Paul Peter | CEO, Dir | — | $3.16M |
| Manning Paul B | Dir | $3.00M | — |
| Barone Francesca | CSO | — | $235.8K |
| Tyagarajan Seshu | CTO | — | $154.2K |
Transactions 110
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-11 18:12 | 2026-09-10 | CADL | Tak Paul Peter | CEO, Dir | M - OptEx | $1.55 | +125.0K | 393.6K | +47% | +$193.8K |
| DMT | 2026-09-11 18:12 | 2026-09-10+ | CADL | Tak Paul Peter | CEO, Dir | S - Sale+OE | $11.28 | -280.2K | 113.3K | -71% | -$3.16M |
| T | 2026-08-19 16:30 | 2026-08-17 | CADL | Tyagarajan Seshu | CTO | S - Sale | $12.00 | -7,000 | 76.9K | -8% | -$84.0K |
| T | 2026-07-01 16:22 | 2026-06-29 | CADL | Barone Francesca | CSO | S - Sale | $10.06 | -23.4K | 77.4K | -23% | -$235.8K |
| T | 2026-07-01 16:22 | 2026-06-29 | CADL | Tyagarajan Seshu | CTO | S - Sale | $10.02 | -7,000 | 83.9K | -8% | -$70.2K |
| I | 2026-02-26 | 2026-02-23 | CADL | Manning Paul B | Dir | P - Purchase | $5.45 | +550.5K | 2.76M | +25% | +$3.00M |
| DT | 2025-07-30 | 2025-07-28 | CADL | Nichols William Garrett | Chief Medical Off | M - OptEx | $1.29 | +937 | 53.4K | +2% | +$1,209 |
| DT | 2025-07-30 | 2025-07-28 | CADL | Nichols William Garrett | Chief Medical Off | S - Sale+OE | $6.98 | -937 | 52.5K | -2% | -$6,540 |
| DT | 2025-07-02 | 2025-06-30 | CADL | Nichols William Garrett | Chief Medical Off | M - OptEx | $1.29 | +781 | 53.3K | +1% | +$1,007 |
| DT | 2025-07-02 | 2025-06-30 | CADL | Nichols William Garrett | Chief Medical Off | S - Sale+OE | $5.04 | -781 | 52.5K | -1% | -$3,936 |
| 2025-06-26 | 2025-06-25 | CADL | Barone Francesca | CSO | A - Grant | $4.67 | +4,282 | 100.8K | +4% | +$20.0K | |
| I | 2025-06-26 | 2025-06-25 | CADL | Manning Paul B | Dir | A - Grant | $4.67 | +1.07M | 2.21M | +94% | +$5.00M |
| 2025-06-26 | 2025-06-25 | CADL | Tak Paul Peter | CEO, Dir | A - Grant | $4.67 | +42.8K | 268.6K | +19% | +$200.0K | |
| I | 2025-06-26 | 2025-06-25 | CADL | Martell Christopher | Dir | A - Grant | $4.67 | +111.3K | 111.3K | New | +$520.0K |
| 2025-06-26 | 2025-06-25 | CADL | Schoch Charles | CFO | A - Grant | $4.67 | +5,353 | 43.4K | +14% | +$25.0K | |
| 2025-06-26 | 2025-06-25 | CADL | Nabel Gary J. | Dir | A - Grant | $4.67 | +5,353 | 5,353 | New | +$25.0K | |
| 2025-06-26 | 2025-06-25 | CADL | Loggia Nicoletta | Dir | A - Grant | $4.67 | +2,141 | 2,141 | New | +$9,998 | |
| I | 2025-06-26 | 2025-06-25 | CADL | PAPA JOSEPH C | Dir | A - Grant | $4.67 | +64.2K | 64.2K | New | +$300.0K |
| 2025-06-26 | 2025-06-25 | CADL | Tyagarajan Seshu | CTO | A - Grant | $4.67 | +5,353 | 90.9K | +6% | +$25.0K | |
| DAT | 2025-03-20 | 2025-03-17 | CADL | Tyagarajan Seshu | CTO | S - Sale+OE | $8.82 | -31.3K | 85.5K | -27% | -$275.9K |
| DAT | 2025-03-20 | 2025-03-17 | CADL | Tyagarajan Seshu | CTO | M - OptEx | $1.29 | +20.0K | 116.8K | +21% | +$25.8K |
| DT | 2025-03-20 | 2025-03-18 | CADL | Barone Francesca | CSO | M - OptEx | $1.55 | +18.0K | 128.7K | +16% | +$27.9K |
| DT | 2025-03-20 | 2025-03-18 | CADL | Barone Francesca | CSO | S - Sale+OE | $8.76 | -32.1K | 96.5K | -25% | -$281.6K |
| MT | 2025-03-20 | 2025-03-18+ | CADL | Tak Paul Peter | CEO, Dir | S - Sale | $8.77 | -26.2K | 226.1K | -10% | -$229.6K |
| DMT | 2025-03-20 | 2025-03-18 | CADL | Nichols William Garrett | Chief Medical Off | M - OptEx | $1.90 | +18.5K | 97.8K | +23% | +$35.1K |
| DT | 2025-03-20 | 2025-03-18 | CADL | Nichols William Garrett | Chief Medical Off | S - Sale+OE | $8.76 | -45.3K | 52.5K | -46% | -$397.0K |
| DT | 2025-03-19 | 2025-03-17 | CADL | Tyagarajan Seshu | CTO | S - Sale | $8.82 | -31.3K | 85.5K | -27% | -$275.9K |
| T | 2025-03-19 | 2025-03-17 | CADL | Schoch Charles | See Remarks | S - Sale | $8.83 | -5,000 | 38.0K | -12% | -$44.1K |
| 2025-02-25 | 2025-02-21 | CADL | Aguilar-Cordova Estuardo | 10% | D - Sale to Iss | $12.02 | -10.6K | 162.9K | -6% | -$127.2K | |
| I | 2025-02-25 | 2025-02-21 | CADL | Aguilar-Cordova Estuardo | 10% | D - Sale to Iss | $12.02 | -10.6K | 120.9K | -8% | -$127.2K |
| 2025-02-13 | 2025-02-10 | CADL | Aguilar-Cordova Estuardo | 10% | D - Sale to Iss | $8.61 | -31.3K | 60.0K | -34% | -$269.8K | |
| 2025-01-17 | 2025-01-15 | CADL | Nichols William Garrett | Chief Medical Off | S - Sale | $7.23 | -10.4K | 79.3K | -12% | -$75.4K | |
| 2025-01-17 | 2025-01-15 | CADL | Schoch Charles | See Remarks | S - Sale | $7.23 | -9,511 | 43.0K | -18% | -$68.8K | |
| 2025-01-17 | 2025-01-15 | CADL | Barone Francesca | CSO | S - Sale | $7.23 | -13.5K | 110.7K | -11% | -$97.9K | |
| 2025-01-17 | 2025-01-15 | CADL | Tak Paul Peter | CEO, Dir | S - Sale | $7.23 | -21.7K | 251.9K | -8% | -$156.9K | |
| 2025-01-17 | 2025-01-15 | CADL | Tyagarajan Seshu | CTO | S - Sale | $7.23 | -14.3K | 96.8K | -13% | -$103.5K | |
| 2025-01-10 | 2025-01-08 | CADL | Tak Paul Peter | CEO, Dir | S - Sale | $8.22 | -21.2K | 273.6K | -7% | -$174.0K | |
| 2025-01-10 | 2025-01-08 | CADL | Barone Francesca | CSO | S - Sale | $8.22 | -13.7K | 124.2K | -10% | -$112.4K | |
| 2025-01-10 | 2025-01-08 | CADL | Nichols William Garrett | Chief Medical Off | S - Sale | $8.22 | -10.8K | 89.7K | -11% | -$88.8K | |
| 2025-01-10 | 2025-01-08 | CADL | Schoch Charles | See Remarks | S - Sale | $8.22 | -9,971 | 52.5K | -16% | -$82.0K | |
| 2025-01-10 | 2025-01-08 | CADL | Tyagarajan Seshu | CTO | S - Sale | $8.22 | -14.5K | 111.1K | -12% | -$119.6K | |
| M | 2024-12-30 | 2024-12-26+ | CADL | Aguilar Laura K. | 10% | D - Sale to Iss | $8.93 | -100.0K | 223.5K | -31% | -$893.0K |
| MI | 2024-12-30 | 2024-12-26+ | CADL | Aguilar Laura K. | 10% | D - Sale to Iss | $8.93 | -100.0K | 131.4K | -43% | -$893.0K |
| MI | 2024-12-26 | 2024-12-20+ | CADL | Aguilar Laura K. | 10% | D - Sale to Iss | $8.84 | -200.0K | 231.4K | -46% | -$1.77M |
| M | 2024-12-26 | 2024-12-20+ | CADL | Aguilar Laura K. | 10% | D - Sale to Iss | $8.84 | -100.0K | 373.5K | -21% | -$883.5K |
| MI | 2024-12-18 | 2024-12-16 | CADL | Manning Paul B | Dir | P - Purchase | $6.00 | +1.25M | 1.30M | +2,325% | +$7.50M |
| M | 2024-12-13 | 2024-12-11+ | CADL | Aguilar-Cordova Estuardo | 10% | D - Sale to Iss | $9.28 | -400.0K | 473.5K | -46% | -$3.71M |
| MI | 2024-12-13 | 2024-12-11+ | CADL | Aguilar-Cordova Estuardo | 10% | D - Sale to Iss | $9.28 | -400.0K | 631.4K | -39% | -$3.71M |
| M | 2024-12-06 | 2024-12-04+ | CADL | Aguilar Laura K. | 10% | D - Sale to Iss | $4.83 | -60.0K | 111.3K | -35% | -$289.6K |
| 2024-12-03 | 2024-11-29 | CADL | Nichols William Garrett | Chief Medical Off | S - Sale | $4.56 | -13.9K | 100.5K | -12% | -$63.5K | |
| 2024-12-03 | 2024-11-29 | CADL | Tyagarajan Seshu | CTO | S - Sale | $4.56 | -20.4K | 125.7K | -14% | -$93.0K | |
| 2024-12-03 | 2024-11-29 | CADL | Barone Francesca | CSO | S - Sale | $4.56 | -22.1K | 137.9K | -14% | -$100.7K | |
| 2024-12-03 | 2024-11-29 | CADL | Tak Paul Peter | CEO, Dir | S - Sale | $4.56 | -48.8K | 294.8K | -14% | -$222.7K | |
| 2024-11-27 | 2024-11-25 | CADL | Aguilar Laura K. | 10% | D - Sale to Iss | $4.97 | -20.0K | 151.3K | -12% | -$99.4K | |
| D | 2024-11-21 | 2024-11-21 | CADL | Tak Paul Peter | CEO, Dir | M - OptEx | $1.55 | +12.9K | 343.6K | +4% | +$20.0K |
| M | 2024-11-08 | 2024-11-06+ | CADL | Aguilar Laura K. | 10% | D - Sale to Iss | $5.15 | -22.5K | 881.0K | -2% | -$115.8K |
| MI | 2024-11-08 | 2024-11-06+ | CADL | Aguilar Laura K. | 10% | D - Sale to Iss | $5.15 | -22.5K | 846.4K | -3% | -$115.8K |
| M | 2024-11-01 | 2024-10-30+ | CADL | Aguilar Laura K. | 10% | D - Sale to Iss | $5.31 | -21.0K | 903.5K | -2% | -$111.6K |
| MI | 2024-11-01 | 2024-10-30+ | CADL | Aguilar Laura K. | 10% | D - Sale to Iss | $5.31 | -21.0K | 853.9K | -2% | -$111.6K |
| M | 2024-10-28 | 2024-10-24+ | CADL | Aguilar Laura K. | 10% | D - Sale to Iss | $5.57 | -30.9K | 900.2K | -3% | -$172.3K |
| M | 2024-10-15 | 2024-10-11+ | CADL | Aguilar-Cordova Estuardo | 10% | S - Sale | $6.03 | -40.4K | 919.5K | -4% | -$243.8K |
| M | 2024-10-03 | 2024-10-01+ | CADL | Aguilar-Cordova Estuardo | 10% | S - Sale | $6.93 | -22.6K | 961.7K | -2% | -$156.5K |
| 2024-07-19 | 2024-07-17 | CADL | Nichols William Garrett | Chief Medical Off | S - Sale | $6.47 | -10.9K | 114.5K | -9% | -$70.4K | |
| 2024-07-19 | 2024-07-17 | CADL | Tak Paul Peter | CEO, Dir | S - Sale | $6.47 | -22.5K | 330.7K | -6% | -$145.8K | |
| 2024-07-19 | 2024-07-17 | CADL | Barone Francesca | CSO | S - Sale | $6.47 | -14.1K | 160.0K | -8% | -$90.9K | |
| 2024-07-19 | 2024-07-17 | CADL | Schoch Charles | See Remarks | S - Sale | $6.47 | -9,884 | 62.5K | -14% | -$63.9K | |
| 2024-07-19 | 2024-07-17 | CADL | Tyagarajan Seshu | CTO | S - Sale | $6.47 | -14.9K | 146.0K | -9% | -$96.1K | |
| 2024-07-15 | 2024-07-11 | CADL | Tak Paul Peter | CEO, Dir | S - Sale | $5.97 | -20.3K | 353.3K | -5% | -$121.1K | |
| 2024-07-15 | 2024-07-11 | CADL | Barone Francesca | CSO | S - Sale | $5.97 | -12.6K | 174.0K | -7% | -$75.5K | |
| 2024-07-15 | 2024-07-11 | CADL | Nichols William Garrett | Chief Medical Off | S - Sale | $5.97 | -9,769 | 125.4K | -7% | -$58.3K | |
| 2024-07-15 | 2024-07-11 | CADL | Schoch Charles | See Remarks | S - Sale | $5.97 | -8,897 | 72.4K | -11% | -$53.1K | |
| 2024-07-15 | 2024-07-11 | CADL | Tyagarajan Seshu | CTO | S - Sale | $5.97 | -13.3K | 160.9K | -8% | -$79.6K | |
| 2023-11-30 | 2023-11-28 | CADL | Barone Francesca | CSO | F - Tax | $0.9 | -19.7K | 186.7K | -10% | -$17.8K | |
| 2023-11-30 | 2023-11-28 | CADL | Tyagarajan Seshu | CTO | F - Tax | $0.9 | -17.3K | 174.2K | -9% | -$15.6K | |
| 2023-11-30 | 2023-11-28 | CADL | Tak Paul Peter | CEO, Dir | F - Tax | $0.9 | -43.4K | 373.6K | -10% | -$39.1K | |
| 2023-11-30 | 2023-11-28 | CADL | Nichols William Garrett | Chief Medical Off | F - Tax | $0.9 | -12.2K | 135.1K | -8% | -$11.0K | |
| 2023-11-30 | 2023-11-28 | CADL | Amello Jason | CFO | F - Tax | $0.9 | -20.2K | 202.0K | -9% | -$18.1K | |
| 2023-11-28 | 2023-11-26 | CADL | Amello Jason | CFO | A - Grant | $0.00 | +125.7K | 222.2K | +130% | $0 | |
| 2023-11-28 | 2023-11-26 | CADL | Tyagarajan Seshu | CTO | A - Grant | $0.00 | +104.5K | 191.6K | +120% | $0 | |
| 2023-11-28 | 2023-11-26 | CADL | Nichols William Garrett | Chief Medical Off | A - Grant | $0.00 | +88.8K | 147.3K | +152% | $0 | |
| 2023-11-28 | 2023-11-26 | CADL | Barone Francesca | CSO | A - Grant | $0.00 | +112.8K | 206.4K | +120% | $0 | |
| 2023-11-28 | 2023-11-26 | CADL | Tak Paul Peter | CEO, Dir | A - Grant | $0.00 | +180.1K | 417.0K | +76% | $0 | |
| MAI | 2023-02-17 | 2022-12-08+ | CADL | Martell Christopher | Dir | P - Purchase | $1.89 | +27.0K | 128.1K | +27% | +$51.1K |
| 2022-12-12 | 2022-12-08 | CADL | Barone Francesca | CSO | P - Purchase | $1.61 | +1,238 | 2,738 | +83% | +$1,993 | |
| M | 2022-12-12 | 2022-12-08+ | CADL | Amello Jason | CFO | P - Purchase | $1.80 | +5,568 | 3,100 | New | +$10.0K |
| M | 2022-12-12 | 2022-12-08+ | CADL | Tyagarajan Seshu | CTO | P - Purchase | $1.88 | +13.4K | 3,000 | New | +$25.1K |
| M | 2022-12-12 | 2022-12-08+ | CADL | Tak Paul Peter | CEO, Dir | P - Purchase | $1.88 | +16.0K | 28.1K | +132% | +$30.0K |
| M | 2022-12-12 | 2022-12-08+ | CADL | PAPA JOSEPH C | Dir | P - Purchase | $1.92 | +38.0K | 3,014 | New | +$73.1K |
| M | 2022-12-12 | 2022-12-08+ | CADL | Martell Christopher | Dir | P - Purchase | $1.89 | +27.0K | 152.0K | +22% | +$51.1K |
| 2022-11-30 | 2022-11-28 | CADL | Tyagarajan Seshu | See Remarks | A - Grant | $0.00 | +73.7K | 73.7K | New | $0 | |
| 2022-11-30 | 2022-11-28 | CADL | Tak Paul Peter | CEO, Dir | A - Grant | $0.00 | +195.9K | 220.9K | +784% | $0 | |
| 2022-11-30 | 2022-11-28 | CADL | Amello Jason | CFO | A - Grant | $0.00 | +90.9K | 90.9K | New | $0 | |
| 2022-11-30 | 2022-11-28 | CADL | Barone Francesca | CSO | A - Grant | $0.00 | +90.9K | 92.4K | +6,058% | $0 | |
| 2022-11-30 | 2022-11-28 | CADL | Nichols William Garrett | Chief Medical Off | A - Grant | $0.00 | +58.5K | 58.5K | New | $0 | |
| D | 2022-05-10 | 2022-05-06 | CADL | Aguilar Laura K. | 10% | F - Tax | $3.65 | -68.5K | 1.03M | -6% | -$250.1K |
| D | 2022-05-10 | 2022-05-06 | CADL | Aguilar Laura K. | 10% | M - OptEx | $1.46 | +171.3K | 1.10M | +18% | +$250.1K |
| D | 2022-05-10 | 2022-05-06 | CADL | Aguilar-Cordova Estuardo | Dir, 10% | M - OptEx | $1.46 | +135.2K | 1.15M | +13% | +$197.4K |
| D | 2022-05-10 | 2022-05-06 | CADL | Aguilar-Cordova Estuardo | Dir, 10% | F - Tax | $3.65 | -54.1K | 1.10M | -5% | -$197.4K |
| DMAI | 2021-08-04 | 2021-07-29 | CADL | Manning Paul B | Dir, 10% | C - Cnv Deriv | — | +1.23M | 679.2K | New | — |
| DA | 2021-08-04 | 2021-07-29 | CADL | Manning Paul B | Dir, 10% | P - Purchase | $8.00 | +1.62M | 1.68M | +2,902% | +$13.00M |
Purchase Sale Sale after option exercise All abbreviations